Bloomberg the Company & Products

Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last A$0.03 AUD
Change Today 0.00 / 0.00%
Volume 0.0
QRX On Other Exchanges
As of 12:54 AM 05/22/15 All times are local (Market data is delayed by at least 15 minutes).

qrxpharma ltd (QRX) Snapshot

Previous Close
Day High
Day Low
52 Week High
05/30/14 - A$0.12
52 Week Low
03/18/15 - A$0.01
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for QRXPHARMA LTD (QRX)

Related News

No related news articles were found.

qrxpharma ltd (QRX) Related Businessweek News

No Related Businessweek News Found

qrxpharma ltd (QRX) Details

QRxPharma Limited develops and commercializes biopharmaceutical products primarily in Australia. It develops proprietary Dual Opioid formulations for treating patients with moderate to severe acute or chronic pain. The company develops pain management products consisting of Moxduo Immediate Release, an oral capsule for the treatment of moderate to severe acute pain; Moxduo Controlled Release oral tablet for chronic pain; and Moxduo Intravenous formulation for hospital-based, post-surgical pain, as well as Pro-drug/Hybrid Dual Opioids. It also offers abuse prevention products, including Stealth Beadlets abuse deterrent technology. QRxPharma Limited is based in North Sydney, Australia.

qrxpharma ltd (QRX) Top Compensated Officers

Chief Executive Officer
Total Annual Compensation: A$441.2K
Chief Financial Officer and Company Secretary
Total Annual Compensation: A$262.8K
Senior Vice President of Global Business Deve...
Total Annual Compensation: A$326.6K
Senior Vice President of Regulatory Affairs a...
Total Annual Compensation: A$65.1K
Compensation as of Fiscal Year 2014.

qrxpharma ltd (QRX) Key Developments

QRxPharma Limited(ASX:QRX) dropped from S&P/ASX All Ordinaries Index

QRxPharma Limited(ASX:QRX) dropped from S&P/ASX All Ordinaries Index

QRxPharma Limited Reports Consolidated Earnings Results for the Half-Year Ended December 31, 2014

QRxPharma Limited reported consolidated earnings results for the half-year ended December 31, 2014. For the period, the company reported loss from continuing operations and net loss attributable to owners of the company of AUD 4.7 million or 2.9 cents per basic and diluted share compared to a net loss of AUD 5.1 million or 3.5 cents per basic and diluted share for the half-year ended December 31, 2013. The company reported revenue from continuing operations of AUD 6,000 compared to AUD 620,000, loss before income tax of AUD 4,737,000 compared to AUD 5,132,000, net cash outflow from operating activities of AUD 5,122,000 compared to AUD 5,962,000 and payments for property, plant and equipment payments for property, plant and equipment of AUD 7,000 compared to AUD 60,000 for the last year.

QRxPharma Limited Reports Preliminary Earnings Results for the Financial Year Ended June 30, 2014

QRxPharma Limited reported preliminary earnings results for the financial year ended June 30, 2014. For the year, the company's revenue from ordinary activities was down 84% to AUD 670,000. Net loss from ordinary activities after tax attributable to members was up 32% to AUD 13,335,000. Net loss from ordinary activities The net loss of AUD 13.3 million against net loss AUD 10.1 million a year ago, resulted from the group's continuing efforts to secure approval for immediate release Moxduo(R), a Dual Opioid(R), for the treatment of moderate to severe acute pain. The net loss includes Research and development expenditure of AUD 6.0 million against AUD 8.3 million in 2013 which includes AUD 3.7 million against AUD 4.4 million in 2013 for clinical and regulatory activities associated with the progression of the NDA for immediate release Moxduo with the FDA, including preparation for the FDA Advisory Committee together with advancing the regulatory filings in Europe, Australia and Canada; with a decrease in spend on product and manufacturing process development to AUD 1.2 million against AUD 2.9 million in 2013.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
QRX:AU A$0.03 AUD 0.00

QRX Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for QRX.
View Industry Companies

Industry Analysis


Industry Average

Valuation QRX Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 43.2x
Price/Book 1.0x
Price/Cash Flow NM Not Meaningful
TEV/Sales NM Not Meaningful

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact QRXPHARMA LTD, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at